



#3

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Fernando DOÑATE et al.

Appl. No. 10/074,225

Filed: February 14, 2002

Art Unit: 1636

Examiner: Unknown

Atty. Docket No. 38342-178463

For: HISTIDINE PROLINE RICH  
GLYCOPROTEIN (HPTG) AS AN  
ANTIANGIOGENIC AND ANTI-  
TUMOR AGENT

Customer No.



26694

PATENT TRADEMARK OFFICE

## INFORMATION DISCLOSURE STATEMENT

Assistant Commissioner for Patents  
Washington, D.C. 20231

Sir:

This is an Information Disclosure Statement submitted under 37 C.F.R. § 1.97 within the time specified under 37 C.F.R. § 1.97(b).


In order to comply with applicant's duty of disclosure under 37 C.F.R. § 1.56, the U.S. Patent and Trademark Office is notified of the documents which are listed on the attached Form PTO-1449 and which the Examiner may deem relevant to patentability of the claims of the above-identified application. One copy of each of the listed documents is submitted herewith.

The present Information Disclosure Statement is being filed before the mailing date of the first Office Action on the merits, and therefore no Statement Under 37 C.F.R. § 1.97(e) or fee under 37 C.F.R. § 1.17(p) is required.

In view of the above, no further translation or statement of relevance is required, and as all requirements of 37 C.F.R. § 1.97 and all official guide lines pertaining to Information Disclosure Statements have been complied with, and it is therefore respectfully requested that the Examiner consider the documents and make them of record.

Please charge any necessary fee or credit any overpayment in connection with this  
Information Disclosure Statement to Deposit Account No. 22-0261.

Respectfully submitted,



\_\_\_\_\_  
Samuel Livnat  
Registration No. 33,949  
VENABLE  
P.O. Box 34385  
Washington, D.C. 20043-9998  
Telephone: (202) 962-4800  
Telefax: (202) 962-8300

Date: June 6, 2002

ASSISTANT COMMISSIONER FOR PATENTS  
Washington, D.C. 20231

Docket No. 38342-178463

PATENT



FORM PTO-1449 (Modified)  
LIST OF PATENTS AND PUBLICATIONS  
FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT  
(Use several sheets if necessary)  
Sheet 1 of 1

In the application of:

Fernando DONATE et al.  
U.S. Application Serial No.: Unassigned  
Filing Date: February 14, 2002

Examiner: Unassigned  
Group Art Unit: 1636

For: HISTIDINE PROLINE RICH GLYCOPROTEIN  
(HPTG) AS AN ANTI-ANGIOGENIC AND  
ANTI-TUMOR AGENT

U.S. PATENT DOCUMENTS

Ref #	Examiner's Initials	Document Number	Date	Name	(If appropriate) Filing Date
-------	------------------------	--------------------	------	------	---------------------------------

FOREIGN PATENT DOCUMENTS

Ref #	Examiner's Initials	Document Number	Date	Country	If appropriate) Filing Date
-------	------------------------	--------------------	------	---------	--------------------------------

OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, etc.)

Ref #	Examiner's Initials
1.	Brown K.J. et al., "Histidine-Rich Glycoprotein And Platelet Factor 4 Mask Heparan Sulfate Proteoglycans Recognized by Acidic and Basic Fibroblast Growth Factor, Biochemistry, 1994, 33:13918.
2.	Borza D-B. et al., "Domain Structure And Conformation of Histidine-Proline-Rich Glycoprotein", Biochemistry, 1996, 35; 1925-1934)
3.	Borza D-B. et al., "Acceleration of Plasminogen Activation by Tissue Plasminogen Activator On Surface-bound Histidine-Proline-Rich Glycoprotein", J. Biol. Chem., 1997, 272:5718-5726
4.	Borza D-B. et al., "Histidine-Proline Rich Glycoprotein as a Plasma pH Sensor", J. Biol. Chem., 1998, 273:5493-5499
5.	Simantov, R. et al., "Histidine-Rich Glycoprotein Inhibits the Antiangiogenic effect of thrombospondon-1", J. Clin. Invest. 107:45-52 (2001)
6.	Morgan W.T., "Histidine-Rich Glycoprotein," In: Encyclopedia of Molecular Medicine, John Wiley & Sons, vol. 3, pages 1644-1647, 2001